Pfizer’s Inlyta (axitinib) approved by FDA
The FDA approved Pfizer’s Inlyta today, according to the Baltimore Sun. Inlyta, brand name for axitinib, is the latest drug to come to market for patients with advanced (metastatic) kidney cancer. Axitinib targets the vascular endothelial growth factor (VEGF) receptor, thereby helping to block the growth of blood vessels to feed the tumors. You can learn more about axitinib, and its results compared to Sorafenib (Nexavar) at Action to Cure Kidney Cancer.